Unverified50% confidenceBenchmarkExact time
Recursion's REC-4881 (a MEK1/2 inhibitor) for familial adenomatous polyposis reduced polyp burden by a median of 43% at week 13 and 53% at week 25.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/17/2026
First Seen
Valid until: 1/15/2027
Sources
Related Entities
Cite This Claim
Stable URI
https://kongchang.com/claim/1055125API
curl https://kongchang.com/api/v1/knowledge/claims/1055125MCP
get_claim(id=1055125)